Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.

ABSTRACT:

Purpose of review

This review summarises the literature data and provides an overview of the role and impact of the use of renin-angiotensin-aldosterone system (RAAS) inhibitors in patients with coronavirus disease 2019 (COVID-19) infection.

Recent findings

The angiotensin-converting enzyme 2 (ACE2) has a key role in the regulation of the RAAS pathway, downregulating angiotensin II and attenuating inflammation, vasoconstriction and oxidative stress. Additionally, it plays an instrumental part in COVID-19 infection as it facilitates the cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enables its replication. The use and role of RAAS inhibitors therefore during the COVID-19 pandemic have been intensively investigated. Although it was initiall

SUBMITTER: Tsampasian V 

PROVIDER: S-EPMC9206216 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature